

# MAGE-D2 (FW.6): sc-130443

## BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens that are expressed in tumors of different histologic types and in normal testis and placenta. MAGE-D2 (melanoma-associated antigen D2), also known as BCG1 (breast cancer-associated gene 1), 11B6, HCA10 or JCL-1, is a 606 amino acid protein that contains one MAGE domain. Expressed throughout the body, MAGE-D2 is thought to function as a negative regulator of p53 (a potent tumor suppressor), possibly contributing to tumor formation and metastasis. Multiple isoforms of MAGE-D2 exist due to alternative splicing events.

## REFERENCES

- Lucas, S., Brasseur, F. and Boon, T. 1999. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. *Cancer Res.* 59: 4100-4103.
- Langnaese, K., Kloos, D.U., Wehnert, M., Seidel, B. and Wieacker, P. 2001. Expression pattern and further characterization of human MAGE-D2 and identification of rodent orthologues. *Cytogenet. Cell Genet.* 94: 233-240.
- Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 300470. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
- Harper, R., Xu, C., Di, P., Chen, Y., Privalsky, M. and Wu, R. 2004. Identification of a novel MAGE-D2 antisense RNA transcript in human tissues. *Biochem. Biophys. Res. Commun.* 324: 199-204.
- Bertrand, M., Huijbers, I., Chomez, P. and De Backer, O. 2004. Comparative expression analysis of the MAGED genes during embryogenesis and brain development. *Dev. Dyn.* 230: 325-334.
- Kidd, M., Modlin, I.M., Mane, S.M., Camp, R.L., Eick, G. and Latich, I. 2006. The role of genetic markers—NAP1L1, MAGE-D2, and MTA1—in defining small-intestinal carcinoid neoplasia. *Ann. Surg. Oncol.* 13: 253-262.
- Papageorgio, C., Brachmann, R., Zeng, J., Culverhouse, R., Zhang, W. and McLeod, H. 2007. MAGE-D2: a novel p53-dissociator. *Int. J. Oncol.* 31: 1205-1211.

## CHROMOSOMAL LOCATION

Genetic locus: MAGED2 (human) mapping to Xp11.21.

## SOURCE

MAGE-D2 (FW.6) is a mouse monoclonal antibody raised against recombinant MAGE-D2 of human origin.

## PRODUCT

Each vial contains 100 µg IgG<sub>1</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

MAGE-D2 (FW.6) is recommended for detection of MAGE-D2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)].

Suitable for use as control antibody for MAGE-D2 siRNA (h): sc-62581, MAGE-D2 shRNA Plasmid (h): sc-62581-SH and MAGE-D2 shRNA (h) Lentiviral Particles: sc-62581-V.


Molecular Weight of MAGE-D2: 65 kDa.

Positive Controls: MCF7 whole cell lysate: sc-2206 or HeLa whole cell lysate: sc-2200.


## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

## DATA



MAGE-D2 (FW.6): sc-130443. Western blot analysis of MAGE-D2 expression in MCF7 whole cell lysate.



MAGE-D2 (FW.6): sc-130443. Western blot analysis of MAGE-D2 expression in HeLa whole cell lysate.

## SELECT PRODUCT CITATIONS

- Yan, J., Li, S., Lenahan, C., Chen, H., Wen, J., Huang, Q., Jiang, Q., Guo, F., Deng, T. and Mo, L. 2022. Expression and prognostic value of melanoma-associated antigen D2 in gliomas. *Brain Sci.* 12: 986.
- Thakur, C., Qiu, Y., Zhang, Q., Carruthers, N.J., Yu, M., Bi, Z., Fu, Y., Wadgaonkar, P., Almutairy, B., Seno, A., Stemmer, P.M. and Chen, F. 2022. Deletion of mdig enhances H3K36me3 and metastatic potential of the triple negative breast cancer cells. *iScience* 25: 105057.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.